Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPPI Trial of enoxaparin to prevent preeclampsia and fetal growth restriction
NL-OMON41162Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in preeclampsia, intrauterine growth restriction (IUGR) and Small for gestational age (SGA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary composite outcome. Started Oct 2014; status: active, not recruiting.
02
Drugs
enoxaparin
03
Conditions
preeclampsiaintrauterine growth restriction (IUGR)Small for gestational age (SGA)
Beyond the preview
Go deeper on NL-OMON41162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41162.